TP53 and acute lymphoblastic leukemia: In addition, Fan et al [119] showed that in relapsed ALL-acquired TP53 R248Q the mutations originate from the cooperation of a thiopurine treatment and an MMR deficiency and are associated with an increased risk of treatment failure [119].